POSTER SESSION V
Wednesday, March 5, 2008   —  9:30 AM - 12:00 Noon
Convention Center Exhibit Hall A


Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...


GENITOURINARY PATHOLOGY



Poster#Title and AuthorsItinerary
Planner
115 ProEx C Is a Better Immunohistochemical Marker in Differentiating between Non-Invasive Low-Grade and High-Grade Papillary Urothelial Carcinomas (830)
J Shi, H Liu, M Wilkerson, F Lin - Gersinger Medical Center, Danville, PA 		Add
116 Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer (803)
HS Park, PE Spiess, N Tanaka, H Katayama, J Bondaruk, JR Steinberg, S Lee, Z Wang, C Dinney, K Baggerly, S Sen, HB Grossman, B Czerniak - The University of Texas M.D. Anderson Cancer Center, Houston, TX 		Add
117 Interleukin-6 and -10 Ratio (IL-6/IL-10) as a Prognostic Marker of Recurrence in Intermediate-Risk Urothelial Bladder Carcinoma Patients (791)
G Nesi, T Cai, S Mazzoli, F Meacci, G Tinacci, E Zini, R Bartoletti - University of Florence, Florence, Italy; Santa Maria Annunziata Hospital, Florence, Italy 		Add
118 Hypoxia-Inducible Factor and Mammalian Target of Rapamycin Pathways in Invasive Urothelial Carcinoma of the Bladder: An Immunohistochemical Study with Potential Therapeutic Implications (843)
SK Tickoo, MI Milowsky, SW Fine, A Gopalan, M Dudas, N Dhar, D Gallagher, DF Bajorin, VE Reuter - MSKCC, New York 		Add
119 HER2 Amplification Affects a Subset of Metastatic Urothelial Carcinomas and Is Often Accompanied by MYC Amplification (728)
DE Hansel, E Swain, RR Tubbs - The Cleveland Clinic, Cleveland, OH 		Add
120 Role of UroVysion® Fluorescence In-Situ Hybridization in the Diagnosis and Surveillance of Squamous Cell Carcinoma of Bladder (814)
MD Reid-Nicholson, SC Peiper, MK Terris, P Ramalingam - Medical College of Georgia, Augusta, GA; VA Hospital, Augusta, GA 		Add
121 An Oncofetal Protein, IMP3: A Novel Biomarker To Predict of Tumor Progression in the Low Grade Ta Urothelial Carcinoma of the Bladder (781)
SK Mohanty, DI Lu, K Dresser, Z Jiang - University of Massachusetts Medical Center., Worcester, MA 		Add
122 Genetic Alterations Detected by FISH (UroVysion® Probe Set) in Non-Urothelial Bladder Cancers (744)
BR Kipp, HL Tyner, MB Campion, TJ Sebo, KC Halling, J Zhang - Mayo Clinic, Rochester 		Add
123 Diagnostic Utility of Commercially Available Prostate Marker for the Detection of Metastatic Prostatic Adenocarcinoma after Androgen Deprivation Therapy: Comparison with Prostate Specific Antigen, Prostate Specific Acid Phosphatase, Prostate Specific Membrane Antigen, and P501s (Prostain) (848)
T Tsuzuki, N Maeda - Nagoya Daini Red Cross Hospital, Nagoya, Japan 		Add
124 Prospective Characterization of the Diagnostic Utility of p63/AMACR Cocktail Immunohistochemistry in the Contemporary Evaluation of Prostate Needle Biopsies (737)
PA Humphrey, O Hameed - Washington University School of Medicine, St. Louis, MO; University of Alabama School of Medicine, Birmingham, AL 		Add
125 CD44 Is a Useful Marker for Prostatic Small Cell Carcinoma (831)
RA Simon, H Xu, PA Bourne, JL Yao, J Wei, S Liang, J Liu, PA di Sant'Agnese, L Cheng, J Huang - University of Rochester Medical Center, Rochester, NY; NYU Medical Center, New York, NY; SUNY Stony Brook Medical Center, Stony Brook, NY; MD Anderson Cancer Center, Houston, TX; Indiana Univeristy School of Medicine, Indianapolis, IN 		Add
126 Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases (798)
AO Osunkoya, DE Hansel, X Sun, GJ Netto, JI Epstein - Emory University School of Medicine, Atlanta, GA; The Cleveland Clinic Foundation, Cleveland, OH; Lakewood Pathology Associates, Lakewood, NJ; The Johns Hopkins Hospital, Baltimore, MD 		Add
127 S100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma from Prostatic Adenocarcinoma (694)
P Cossu-Rocca, M Contini, M Brunelli, A Festa, F Pili, S Gobbo, A Eccher, A Mura, G Massarelli, G Martignoni - University of Sassari, Sassari, Italy; University of Verona, Verona, Italy 		Add
128 Prognostic Value of Chromogranin-A in Prostate Cancer. A Clinicopathological, Immunohistochemical and Molecular Study of 112 Cases (747)
JI López, A Ferruelo, B Colás, P López-Ruiz, FJ Bilbao, JC Angulo - Hospital de Cruces, Basque Country Univ, Barakaldo, Bizkaia, Spain; Hospital de Getafe, Getafe, Madrid, Spain; University of Alcalá, Alcalá de Henares, Madrid, Spain; Hospital de Basurto, Basque Country Univ, Bilbao, Bizkaia, Spain 		Add
129 Prognostic Role of Cell Apoptotic Rate in Prostate Cancer Patients after Radical Prostatectomy (792)
G Nesi, T Cai, G Dachille, LR Girardi, N Mondaini, R Bartoletti - University of Florence, Florence, Italy; Hospital of Monopoli, Bari, Italy 		Add
130 Prognostic Value of p16, PTEN, E-cadherin, and bcl-2 Expression in High Risk Prostate Cancer of Korean Patients (743)
MJ Kim, JM Kim, WJ Sung, SH Seok, AR Kim, WS Im, DC Park - College of Medicine, Yeungnam University, Daegu, Republic of Korea 		Add
131 KI-67 Is an Independent Predictor of Outcome in Conservatively Treated Clinically Localised Prostate Cancer (671)
DM Berney, A Gopalan, S Kudahetti, L Ambroisine, G Fisher, M Kattan, H Moller, C Foster, V Reuter, J Cuzick, P Scardino, C Cooper, W Gerald - Barts and The London School of Medicine, London, United Kingdom; Memorial Sloan Kettering, New York; The Cleveland Clinic, Cleveland; The Royal Marsden Hospital, United Kingdom; King's College London 		Add
132 Elevated Tenascin Expression in Stroma near Focally Disrupted Prostate Basal Cell Layers: Implications for Tumor Progression and Invasion (771)
YG Man, AJ Liu, WA William - Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC; Beijing 301 Hospital, Beijing, China 		Add
133 Co-Overexpression of SmgGDS and COX-2 in Prostate Carcinoma (707)
MB Ferrer, HY Zhi, XJ Yang, J Kuhnmuench, LL Dionisi, HY Yang, CL Williams, R Li - Medical College of Wisconsin, Milwaukee, WI; Weill Medical College of Cornell University, New York, NY 		Add
134 Neural Precursor Cell-Expressed Developmentally Down-Regulared 8 Is Up-Regulated in Prostatic Adenocarcinoma and Correlates with Gleason Grade (767)
S Lu, CE Sheehan, TA Jennings, B Mian, HAT Nazeer, JS Ross, T Nazeer - Albany Medical College, Albany, NY 		Add
135 SIRT1 Expression Is Elevated in Human Prostate Cancer (884)
YF Zhang, Q Zhou, YJ Jiang, Y Dai, Q Huang - Nanjing Drum Tower Hospital, Nanjing, China; Boston University Medical Center, Boston; Boston VA Health Care System and Brown University, West Roxbury 		Add
136 Heat Shock Proteins 27, 60 and 70 as Prognostic Markers of Prostate Cancer (714)
A Glaessgen, S Jonmarker, B Nilsson, R Lewensohn, P Ekman, A Valdman, L Egevad - Karolinska Institute, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden; International Agency for Research on Cancer, Lyon, France 		Add
137 B7-H3 and B7x Are Highly Expressed in Human Prostate Cancer and Associated with Disease Spread and Poor Outcome (655)
HA Al-Ahmadie, X Zang, RH Thompson, AM Serio, JA Eastham, PT Scardino, P Sharma, JP Allison, VE Reuter - Memorial Sloan-Kettering Cancer Center, New York, NY 		Add
138 Differential Expression of Angiopoietin Receptor Tie-2 in the Benign and Malignant Prostate: A Tissue Microarray Study (874)
JL Yao, Y Sun, PA Bourne, PA di Sant'Agnese, J Huang - University of Rochester Medical Center, Rochester, NY 		Add
139 Tissue Factor and VEGF Expression in the Benign and Malignant Prostate: A Tissue Microarray Study (873)
JL Yao, AA Khorana, CW Francis, M Kohli, MB Taubman, CK Ryan - University of Rochester Medical Center, Rochester, NY 		Add
140 Expression of Aurora Kinase B in Urothelial Carcinoma (682)
YB Chen, M Schwartz, N Kitabayashi, M Hsu, DS Scherr, Y-T Chen - Weill Cornell Medical College, New York, NY 		Add